查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1479066

全球干细胞检测市场评估：依检测类型、依细胞类型、依产品类型、依应用类型、依最终用户、依地区、机会、预测（2017-2031）

Stem Cell Assays Market Assessment, By Assay Type, By Cell Type, By Product Type, By Application Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 223 Pages | 商品交期: 3-5个工作天内

价格

全球干细胞检测市场规模预计将从 2023 年的 15.4 亿美元增至 2031 年的 48 亿美元，在 2024-2031 年的预测期内复合年增长率将达到 15.27%。 近年来市场呈现显着成长，预计未来将维持稳定扩张速度。 干细胞测定是评估干细胞特性和作用的实验方法。 干细胞在受控条件下进行测试，以评估其自我更新、分化成不同细胞类型和增殖的能力。 干细胞检测在生物医学研究和再生医学中非常重要，其应用范围从药物发现和开发到毒理学筛检和疾病建模。 此外，干细胞检测透过检查潜在治疗剂对干细胞分化和功能的影响，在药物开发中发挥重要作用。 此外，这些测定也用于研究发育过程、筛选药理学毒性以及研究癌症和神经系统疾病等疾病的根本原因。

干细胞研究的不断进步以及干细胞分离、培养和分化创新技术的出现是主要驱动因素。 这些技术进步提高了干细胞检测的效率和有效性，使其对药物发现、再生医学和基础研究等各种应用越来越有吸引力。 3D 细胞培养方法、高通量筛选方法以及成像和分析仪器的进步等创新共同促进了市场的扩张。

干细胞在治疗心血管疾病、神经系统疾病和糖尿病等多种疾病方面的潜力，以及人们对再生医学的兴趣迅速增长，正在推动对干细胞检测的需求。 此外，世界各地慢性病和遗传疾病的增加需要开发新的治疗剂和治疗方法。 干细胞代表了产生此类疗法的有前途的途径，推动了疾病建模、药物开发和个人化医疗中对干细胞测定的需求。 随着学术界和製药公司加强提高我们对疾病发病机制的瞭解并评估新疗法，对干细胞检测的需求持续增长。 政府、企业和学术机构正在增加对干细胞研究的投资，以探索治疗应用，从而产生对评估干细胞疗法的功效和安全性的检测的需求。 例如，FUJIFILM Cellular Dynamics 于 2022 年 3 月与 Promega Corporation 合作开发了新的检测方法，以瞭解细胞生物学在系统中的工作原理，从而最终瞭解人类细胞生物学。

疾病盛行率增加

癌症、心血管疾病、糖尿病和神经系统疾病等慢性病和生活型态相关疾病的盛行率不断上升，已成为干细胞检测市场扩张的关键催化剂。 猪流感和伊波拉等传染病的快速成长也刺激了治疗和药物开发领域的成长。 例如，从2021年12月27日到2022年1月9日，世卫组织全球流感监测和回应系统（GISRS）实验室分析了来自99个国家实验室的超过317,198个样本。 在这些检测中，16,862人的流感病毒检测呈阳性，其中63.7%为甲型流感，36.3%为B型流感。 疾病的流行及其復发性证明了干细胞检测在瞭解和对抗这些疾病方面的重要性。 此外，随着老年人和儿童人口的增加，疾病的盛行率也随之增加，进一步推动了对干细胞检测的需求。 截至2022年7月，联合国预测全球儿童人口（0-17岁）为23亿，预计2040年将达25亿。 儿科人口的持续成长意味着对创新解决方案的需求不断增加，干细胞检测市场预计在未来几年将持续成长。

本报告研究和分析了全球干细胞检测市场，提供市场规模和预测、市场动态、主要参与者的现状和前景等。

目录

第一章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第四章全球干细胞检测市场展望（2017-2031）

  • 市场规模与预测
    • 金额
    • 数量
  • 依检测类型
    • 活力/细胞毒性测定
    • 分离/纯化测定
    • 细胞鑑定分析
    • 增殖测定
    • 分化分析
    • 功能测定
    • 细胞凋亡检测
  • 依细胞类型
    • 成体干细胞
    • 人类胚胎干细胞
  • 产品类型
    • 设备
    • 试剂、试剂盒
  • 依使用型
    • 再生医学/治疗方法开发
    • 药物发现与药物开发
    • 临床研究
  • 依最终用户
    • 生物製药和生物技术公司
    • 学术机构、研究设施
    • 其他
  • 依地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲最终用户
    • 中东/非洲
  • 市占率：依公司划分（2023 年）

第 5 章全球干细胞检测市场展望：依地区划分（2017-2031 年）

  • 北美
    • 市场规模与预测
    • 依检测类型
    • 依细胞类型
    • 产品类型
    • 依使用型
    • 依最终用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印尼
    • 菲律宾
  • 南美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 南非

第 6 章市场地图（2023 年）

  • 依检测类型
  • 依细胞类型
  • 产品类型
  • 依使用型
  • 依最终用户
  • 依地区

第七章宏观环境与产业结构

  • 需求与供给分析
  • 进出口分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 抑製成长的因素（问题、限制因素）

第 9 章监理架构与创新

  • 临床试验
  • 创新/新技术

第十章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析（2023 年）
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家市场公司）
  • 专利分析（如果适用）

第11章价格分析

第 12 章案例研究

第十三章主要公司展望

  • GE Healthcare Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Merck & Co., Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Promega Corporation
  • Cell Biolabs, Inc.
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Fujifilm Holdings Corporation

第14章战略建议

第十五章关于我们公司，免责声明

Product Code: MX11317

Global stem cell assays market is projected to witness a CAGR of 15.27% during the forecast period 2024-2031, growing from USD 1.54 billion in 2023 to USD 4.8 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years. A stem cell assay is a laboratory method used to evaluate the characteristics and actions of stem cells. It involves testing stem cells under controlled conditions to assess their capacity for self-renewal, differentiation into various cell types, and proliferation. Stem cell assays are important in biomedical research and regenerative medicine, offering applications ranging from drug discovery and development to toxicological screening and disease modeling. Moreover, stem cell assays play a crucial role in drug development by examining the effects of potential therapeutic drugs on stem cell differentiation and functionality. Additionally, these assays are employed to study developmental processes, screen for pharmacological toxicities, and investigate the underlying causes of diseases such as cancer and neurological disorders.

Constant progress in stem cell research, coupled with the emergence of innovative techniques for stem cell isolation, cultivation, and differentiation, serve as primary drivers. These technological advancements enhance the efficiency and efficacy of stem cell assays, rendering them increasingly attractive for various applications, including drug development, regenerative medicine, and fundamental research. Innovations such as 3D cell culture methodologies, high-throughput screening approaches, and advancements in imaging and analytical instruments collectively contribute to market expansion.

The burgeoning interest in regenerative medicine, alongside the potential of stem cells to address various ailments such as cardiovascular disease, neurological disorders, and diabetes, fuels the demand for stem cell assays. Moreover, the rising global prevalence of chronic diseases and genetic disorders necessitates the development of novel therapeutics and treatments. Stem cells offer a promising avenue for generating such therapies, consequently driving the demand for stem cell assays in disease modeling, drug development, and personalized medicine. As academia and pharmaceutical companies intensify efforts to deepen their understanding of disease etiology and evaluate new treatments, the necessity for stem cell assays continues to grow. Governments, corporations, and academic institutions are increasingly investing in stem cell research to explore therapeutic applications, thereby generating demand for assays to assess stem cell-based therapies' efficacy and safety. For instance, Fujifilm cellular dynamics collaborated with Promega Corporation in March 2022 to develop novel assays to understand how cellular biology works in a system to understand cell biology in humans ultimately.

Rising Prevalence of Diseases

The increasing prevalence of chronic diseases and lifestyle-related disorders, including cancer, cardiovascular conditions, diabetes, and neurological ailments, serves as a significant catalyst for the expansion of the stem cell assay market. The upsurge in infectious diseases, such as swine flu and Ebola, has also fueled growth in the therapeutics and drug development sector. For instance, between December 27, 2021, and January 9, 2022, WHO Global Influenza Surveillance and Response System (GISRS) laboratories analyzed over 317,198 specimens from labs across 99 countries. Among these tests, 16,862 individuals tested positive for influenza viruses, with 63.7% identified as influenza A and 36.3% as influenza B. The prevalence of diseases and their recurring nature underscore the importance of stem cell assays in understanding and combating these conditions. Moreover, the expanding geriatric and pediatric populations drive the increased incidence of diseases, further boosting the demand for stem cell assays. As of July 2022, United Nations Projections indicated a global pediatric population (0-17 years) of 2.3 billion, projected to reach 2.5 billion by 2040. The ongoing rise in the pediatric population signifies a growing need for innovative solutions, positioning the stem cell assays market for sustained growth in the coming years.

Growing Emphasis On Clinical Research & Development

The expansion of the global stem cell assays market is being propelled by factors such as clinical research and development. There is a strong emphasis on comprehending cancer biology and identifying innovative therapeutic targets for a wide range of acute and chronic diseases, significantly contributing to the growth of the stem cell assays market. Moreover, substantial investments in research and development endeavors by pharmaceutical companies and academic institutions are fostering market expansion. The escalating prevalence of chronic diseases such as cancer, osteoarthritis, cardiovascular diseases, and diabetes drives the demand for cell-based assays in the quest for novel drug discoveries, thereby serving as a pivotal growth factor for this market segment. According to an article titled "2022 Funding forecast: strong R&D growth with clouds on the horizon," published in April 2022, the United States federal government is projected to allocate USD 181.4 billion for research and development in 2022, further bolstering growth prospects for this segment.

Clinical trials play a pivotal role in assessing the safety and efficacy of new drugs, ultimately leading to regulatory approvals and market penetration. These trials validate the therapeutic potential of drugs and augment the empirical evidence supporting their clinical utility. Additionally, collaboration among commercial entities, academic institutions, and regulatory bodies expedites the clinical development process of various stem cell assays and accelerates the introduction of novel drugs to the market. In April 2023, Omisirge (omidubicel-onlv), a significantly modified allogeneic (donor) cord blood-based cell therapy was granted approval by US FDA.

Dominance of Reagent and Kits

During the projected period, the reagents and kits segment are expected to lead the stem cell assays market. These consumables play a vital role in various stem cell tests, encompassing cell proliferation, differentiation, viability, and toxicity assessments. Their pervasive use in routine laboratory operations and recurring necessity contribute to their high demand. This demand is fueled by ongoing research and development endeavors in both academic and commercial sectors, where stem cell assays are pivotal for drug discovery, therapeutic advancement, and fundamental research. Reagents and kits are formulated to address a broad spectrum of requirements, ranging from fundamental research to specialized therapeutic domains. This adaptability is reinforced by the capacity to customize kits for specific stem cell types or assays. Such tailored solutions and application versatility ensure sustained high demand for reagents and kits across diverse research domains and pharmaceutical development initiatives, consolidating their market dominance. Moreover, in contrast to instruments, which entail significant upfront capital investment and maintenance costs, reagents and kits are more cost-effective and accessible to a broader customer base, including small research laboratories and entrepreneurs. In March 2022, Illumina launched the TruSight Oncology (TSO) comprehensive in-vitro genomic profiling kit in Europe. The kit evaluates multiple genes and biomarkers to elucidate the precise molecular profile of cancer patients, empowering clinicians to administer tailored therapies based on individual molecular profiles.

North America Dominates Global Stem Cell Assays Market Share

North America dominates the global stem cell assays market, primarily due to its well-established healthcare sector and widespread adoption of cell-based assays. In the United States, the rising incidence of chronic diseases like cancer, osteoarthritis, and diabetes drives demand for cell-based assays, thus serving as a significant growth driver for this market.

For instance, according to data from the American Cancer Society's Cancer Facts & Figures 2022 report, an estimated 1.9 million new cancer cases will be diagnosed in the United States, along with 609,360 cancer-related deaths. Similarly, American Heart Association reported in January 2022 that a myocardial infarction occurs approximately every 40 seconds in the United States. Such high prevalence of chronic diseases in the population of the United States is expected to propel stem cell assays market growth during the forecast period.

Future Market Scenario (2024 - 2031F)

Occurrence and re-occurrence in number of acute and non-acute diseases call for a solution and it presents the biggest opportunity for the stem cell assays market to rise. Adoption of much advanced and effective approaches are being devised that should ensure faster recovery and better results for a better quality of life. R&D and heavy investments made by healthcare giants are promoting developments in the stem cell assays market, which is optimistic for the market to flourish in the coming years. New brands in this development area are introducing themselves with cutting edge technologies.

For instance, in February 2024, Thermo Fisher unveiled a novel serum-free stem cell culture medium designed to enhance stem cell proliferation and differentiation. The breakthrough holds significant promise for companies engaged in developing stem cell-based therapies. Successful attempts to improve diagnostics push the industry as a whole to engage further with higher-quality R&D, which paves the way for the market to rise. In August 2022, Life Net Health LifeSciences launched Cell-Based Assay Services, including cytotoxicity screening, biocompatibility assays, and others.

Key Players Landscape and Outlook

Several companies in global stem cell assays market are focusing on new product release, market expansion, and product development. Stem cell assays market players are poised to encounter promising growth prospects in the global market, driven by the increasing demand for diagnostic solutions. The primary focus of these leading players is directed towards the rapidly expanding market segment, aiming to thrive and excel in an intensely competitive market environment. Additionally, these market players emphasize collaboration and license agreements as strategic initiatives are anticipated to propel the market growth.

In July 2022, CORESTEM, based in South Korea, continued to enroll participants for the Phase 3 clinical trial of NeuroNata-R. The treatment has obtained conditional approval for the treatment of amyotrophic lateral sclerosis (ALS) patients in South Korea.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Stem Cell Assays Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Assay Type
    • 4.2.1.Viability/Cytotoxicity Assays
    • 4.2.2.Isolation & Purification Assays
    • 4.2.3.Cell Identification Assays
    • 4.2.4.Proliferation Assays
    • 4.2.5.Differentiation Assays
    • 4.2.6.Function Assays
    • 4.2.7.Apoptosis Assays
  • 4.3.By Cell Type
    • 4.3.1.Adult Stem Cells
    • 4.3.2.Human Embryonic Stem Cells
  • 4.4.By Product Type
    • 4.4.1.Instruments
    • 4.4.2.Reagents and Kits
  • 4.5.By Application Type
    • 4.5.1.Regenerative Medicine & Therapy Development
    • 4.5.2.Drug Discovery & Development
    • 4.5.3.Clinical Research
  • 4.6.By End-user
    • 4.6.1.Biopharmaceutical and Biotechnology Companies
    • 4.6.2.Academic Institutes and Research Facilities
    • 4.6.3.Others
  • 4.7.By Region
    • 4.7.1.North America
    • 4.7.2.Europe
    • 4.7.3.Asia-Pacific
    • 4.7.4.South End-user America
    • 4.7.5.Middle East and Africa
  • 4.8.By Company Market Share (%), 2023

5.Global Stem Cell Assays Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Assay Type
      • 5.1.2.1.Viability/Cytotoxicity Assays
      • 5.1.2.2.Isolation & Purification Assays
      • 5.1.2.3.Cell Identification Assays
      • 5.1.2.4.Proliferation Assays
      • 5.1.2.5.Differentiation Assays
      • 5.1.2.6.Function Assays
      • 5.1.2.7.Apoptosis Assays
    • 5.1.3.By Cell Type
      • 5.1.3.1.Adult Stem Cells
      • 5.1.3.2.Human Embryonic Stem Cells
    • 5.1.4.By Product Type
      • 5.1.4.1.Instruments
      • 5.1.4.2.Reagents and Kits
    • 5.1.5.By Application Type
      • 5.1.5.1.Regenerative Medicine & Therapy Development
      • 5.1.5.2.Drug Discovery & Development
      • 5.1.5.3.Clinical Research
    • 5.1.6.By End-user
      • 5.1.6.1.Biopharmaceutical and Biotechnology Companies
      • 5.1.6.2.Academic Institutes and Research Facilities
      • 5.1.6.3.Others
    • 5.1.7.United States*
      • 5.1.7.1.Market Size & Forecast
        • 5.1.7.1.1.By Value
        • 5.1.7.1.2.By Volume
      • 5.1.7.2.By Assay Type
        • 5.1.7.2.1.Viability/Cytotoxicity Assays
        • 5.1.7.2.2.Isolation & Purification Assays
        • 5.1.7.2.3.Cell Identification Assays
        • 5.1.7.2.4.Proliferation Assays
        • 5.1.7.2.5.Differentiation Assays
        • 5.1.7.2.6.Function Assays
        • 5.1.7.2.7.Apoptosis Assays
      • 5.1.7.3.By Cell Type
        • 5.1.7.3.1.Adult Stem Cells
        • 5.1.7.3.2.Human Embryonic Stem Cells
      • 5.1.7.4.By Product Type
        • 5.1.7.4.1.Instruments
        • 5.1.7.4.2.Kits and Reagents
      • 5.1.7.5.By Application Type
        • 5.1.7.5.1.Regenerative Medicine & Therapy Development
        • 5.1.7.5.2.Drug Discovery & Development
        • 5.1.7.5.3.Clinical Research
      • 5.1.7.6.By End-user
        • 5.1.7.6.1.Biopharmaceutical and Biotechnology Companies
        • 5.1.7.6.2.Academic Institutes and Research Facilities
        • 5.1.7.6.3.Others
    • 5.1.8.Canada
    • 5.1.9.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Assay Type
  • 6.2.By Cell Type
  • 6.3.By Product Type
  • 6.4.By Application Type
  • 6.5.By End-user
  • 6.6.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.GE Healthcare Technologies Inc.
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Thermo Fisher Scientific Inc.
  • 13.3.Merck & Co., Inc.
  • 13.4.Bio-Rad Laboratories, Inc.
  • 13.5.Bio-Techne Corporation
  • 13.6.Promega Corporation
  • 13.7.Cell Biolabs, Inc.
  • 13.8.Danaher Corporation
  • 13.9.Becton, Dickinson and Company
  • 13.10.Fujifilm Holdings Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 3.Global Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 4.Global Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 5.Global Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 6.Global Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 7.Global Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 8.Global Stem Cell Assays Market Share (%), By Region, 2017-2031F
  • Figure 9.North America Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 10.North America Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 11.North America Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 12.North America Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 13.North America Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 14.North America Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 15.North America Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 16.North America Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 17.United States Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 18.United States Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 19.United States Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 20.United States Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 21.United States Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 22.United States Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 23.United States Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 24.Canada Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 25.Canada Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 26.Canada Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 27.Canada Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 28.Canada Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 29.Canada Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 30.Canada Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 31.Mexico Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 32.Mexico Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 33.Mexico Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 34.Mexico Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 35.Mexico Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 36.Mexico Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 37.Mexico Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 38.Europe Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 39.Europe Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 40.Europe Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 41.Europe Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 42.Europe Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 43.Europe Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 44.Europe Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 45.Europe Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 46.Germany Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.Germany Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 48.Germany Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 49.Germany Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 50.Germany Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 51.Germany Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 52.Germany Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 53.France Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 54.France Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 55.France Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 56.France Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 57.France Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 58.France Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 59.France Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 60.Italy Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 61.Italy Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 62.Italy Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 63.Italy Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 64.Italy Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 65.Italy Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 66.Italy Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 67.United Kingdom Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 68.United Kingdom Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 69.United Kingdom Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 70.United Kingdom Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 71.United Kingdom Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 72.United Kingdom Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 73.United Kingdom Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 74.Russia Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 75.Russia Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 76.Russia Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 77.Russia Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 78.Russia Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 79.Russia Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 80.Russia Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 81.Netherlands Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 82.Netherlands Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 83.Netherlands Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 84.Netherlands Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 85.Netherlands Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 86.Netherlands Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 87.Netherlands Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 88.Spain Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Spain Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 90.Spain Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 91.Spain Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 92.Spain Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 93.Spain Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 94.Spain Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 95.Turkey Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 96.Turkey Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 97.Turkey Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 98.Turkey Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 99.Turkey Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 100.Turkey Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 101.Turkey Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 102.Poland Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 103.Poland Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 104.Poland Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 105.Poland Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 106.Poland Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 107.Poland Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 108.Poland Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 109.South America Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 110.South America Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 111.South America Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 112.South America Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 113.South America Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 114.South America Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 115.South America Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 116.South America Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 117.Brazil Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 118.Brazil Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 119.Brazil Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 120.Brazil Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 121.Brazil Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 122.Brazil Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 123.Brazil Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 124.Argentina Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 125.Argentina Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 126.Argentina Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 127.Argentina Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 128.Argentina Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 129.Argentina Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 130.Argentina Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 131.Asia-Pacific Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 132.Asia-Pacific Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 133.Asia-Pacific Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 134.Asia-Pacific Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 135.Asia-Pacific Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 136.Asia-Pacific Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 137.Asia- Pacific Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 138.Asia-Pacific Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 139.India Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 140.India Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 141.India Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 142.India Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 143.India Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 144.India Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 145.India Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 146.China Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 147.China Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 148.China Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 149.China Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 150.China Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 151.China Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 152.China Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 153.Japan Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 154.Japan Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 155.Japan Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 156.Japan Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 157.Japan Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 158.Japan Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 159.Japan Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 160.Australia Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 161.Australia Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 162.Australia Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 163.Australia Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 164.Australia Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 165.Australia Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 166.Australia Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 167.Vietnam Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 168.Vietnam Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 169.Vietnam Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 170.Vietnam Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 171.Vietnam Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 172.Vietnam Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 173.Vietnam Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 174.South Korea Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 175.South Korea Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 176.South Korea Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 177.South Korea Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 178.South Korea Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 179.South Korea Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 180.South Korea Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 181.Indonesia Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.Indonesia Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 183.Indonesia Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 184.Indonesia Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 185.Indonesia Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 186.Indonesia Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 187.Indonesia Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 188.Philippines Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 189.Philippines Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 190.Philippines Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 191.Philippines Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 192.Philippines Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 193.Philippines Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 194.Philippines Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 195.Middle East & Africa Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 196.Middle East & Africa Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 197.Middle East & Africa Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 198.Middle East & Africa Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 199.Middle East & Africa Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 200.Middle East & Africa Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 201.Middle East & Africa Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 202.Middle East & Africa Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 203.Saudi Arabia Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 204.Saudi Arabia Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 205.Saudi Arabia Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 206.Saudi Arabia Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 207.Saudi Arabia Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 208.Saudi Arabia Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 209.Saudi Arabia Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 210.UAE Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 211.UAE Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 212.UAE Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 213.UAE Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 214.UAE Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 215.UAE Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 216.UAE Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 217.South Africa Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 218.South Africa Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 219.South Africa Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 220.South Africa Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 221.South Africa Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 222.South Africa Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 223.South Africa Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 224.By Assay Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225.By Cell Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226.By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227.By Application Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023